On August 19, Bristol-Myers Squibb rose 3.11% in regular trading, trading at $68.005/share, with turnover of $113 million.

On the news front, the FDA granted accelerated approval on August 14 to Bristol-Myers Squibb's first Celmod therapy Zenbexus in combination with daratumumab, hyaluronidase-fihj, and dexamethasone for the treatment of adults with multiple myeloma who have received at least one prior line of therapy. Phase 3 clinical data demonstrated a statistically significant improvement, with minimal residual disease-negative complete response achieved in 41% of patients treated with the Zenbexus combination versus 21% for the comparator regimen. Full approval will depend on verification of clinical benefit in a confirmatory trial.

Additionally, the broader pharmaceutical sector posted strong gains on the day, with Merck rising 10.3%, Eli Lilly up 4.36%, and Pfizer gaining 3.23%, providing further sector-wide momentum to Bristol-Myers Squibb shares.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)